SCHEMBL455566

SCHEMBL455566

Cn1cnc(S(=O)(=O)NCCNc2ccc(C(=O)O)cc2)c1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.52
KMT2A Q03164 5/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
TSHR P16473 1/20 0.47
ALDH1A1 P00352 2/20 0.46
GAA P10253 2/20 0.46
MAPK1 P28482 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MEN1 O00255 2/20 0.42
NPY5R Q15761 1/20 0.42
KDM4D Q6B0I6 1/20 0.39
TP53 P04637 1/20 0.39
KDM4E B2RXH2 1/20 0.39
HRH2 P25021 1/20 0.38
HRH1 P35367 1/20 0.38
GLO1 Q04760 1/20 0.37
MEP1B Q16820 1/20 0.37
HTR6 P50406 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15124776 0.85 ALDH1A1 (0.47) LMNAKMT2AL3MBTL1TSHRALDH1A1
SCHEMBL456368 0.76 MEN1 (0.54) LMNAKMT2AMEN1
SCHEMBL9034666 0.73 LMNA (0.60) LMNAKMT2AL3MBTL1TSHRALDH1A1
SCHEMBL9032107 0.73 LMNA (0.53) LMNAKMT2AALDH1A1GAANPY5R
SCHEMBL11403189 0.72 ALDH1A1 (0.62) LMNAKMT2AALDH1A1SMN1; SMN2MEN1
SCHEMBL9034060 0.72 LMNA (0.56) LMNAKMT2AL3MBTL1TSHRALDH1A1
Hydrochloric Acid SCHEMBL9400437 0.71 LMNA (0.55) LMNAKMT2AL3MBTL1TSHRALDH1A1
SCHEMBL15124128 0.71 LTA4H (0.40) LMNAKMT2ATSHRMAPK1MEN1
SCHEMBL6400068 0.71 HRH2 (0.50) LMNAKMT2AL3MBTL1ALDH1A1GAA
SCHEMBL9400533 0.70 LMNA (0.53) LMNAKMT2AL3MBTL1TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9040563-B2 Dual inhibitors of farnesyltransferase and geranylgeranyltransferase I H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2015-05-26 US disclosed
US-20130190355-A1 DUAL INHIBITORS OF FARNESYLTRANSFERASE AND GERANYLGERANYLTRANSFERASE I YALE UNIVERSITY (US) 2013-07-25 US disclosed
WO-2012034038-A2 DUAL INHIBITORS OF FARNESYLTRANSFERASE AND GERANYLGERANYLTRANSFERASE I H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2012-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190355-A1 DUAL INHIBITORS OF FARNESYLTRANSFERASE AND GERANYLGERANYLTRANSFERASE I FNTA, FNTB, GDI1 LMNA 1823/4885KMT2A 3248/4885L3MBTL1 386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.